[{"id":"cf479511-33a8-4419-9457-da0adfcc87ec","acronym":"IMM01-04","url":"https://clinicaltrials.gov/study/NCT05833984","created_at":"2023-04-27T14:05:17.425Z","updated_at":"2024-07-02T16:35:49.439Z","phase":"Phase 1b/2","brief_title":"Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas","source_id_and_acronym":"NCT05833984 - IMM01-04","lead_sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • timdarpacept (IMM01)"],"overall_status":"Recruiting","enrollment":" Enrollment 309","initiation":"Initiation: 05/17/2022","start_date":" 05/17/2022","primary_txt":" Primary completion: 02/07/2024","primary_completion_date":" 02/07/2024","study_txt":" Completion: 11/20/2024","study_completion_date":" 11/20/2024","last_update_posted":"2023-04-27"}]